Armetheon Seeks to Repurpose Stalled Late-Stage Compounds
Privately held Armetheon Inc. was launched in October 2011 with a mission to create novel antibiotics for drug-resistant bacteria. However, that program quickly took a back seat when the founders discovered a new use for a compound, tecarfarin, advanced by another biotech where several of them had played leading roles.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter